Liver Fibrosis
Apr 14, 2025
Redefining Liver Disease in the Metabolic Era: From NASH to MASH and the Rise of Obesity‐targeted Therapies
The paradigm shift from Non‐alcoholic Steatohepatitis (NASH) to Metabolic Dysfunction–associated Steatohepatitis (MASH) reflects a deeper understanding of the pathophysiology underpinning liver injury in the context of obesity, diabetes, and metabolic syndrome. This evolving nomenclature from NASH to MASH is more t...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
